DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
6532
MBX-2982
2
Small molecule
Investigational
Unknown
Unknown
Diabetes Mellitus; Diabetes Mellitus, Type 1
Glucose-dependent insulinotropic receptor agonist
MBX-2982
×
Maximum Phase:
2
First Approval:
None
UNII:
B5TRY67L51
Molecule Type:
Small molecule
Molecular Formula:
C22H24N8OS
Molecular Weight:
448.56
AlogP:
3.43
PSA:
94.74
HBD:
0.0
HBA:
#RotB:
7.0
Source:
LEMUTEPORFIN
2
Small molecule
Investigational
Unknown
Unknown
Acne Vulgaris; Prostatic Hyperplasia
Unknown
LEMUTEPORFIN
×
Maximum Phase:
2
First Approval:
None
UNII:
EZ109VJ012
Molecule Type:
Small molecule
Molecular Formula:
C45H50N4O9
Molecular Weight:
790.91
AlogP:
6.84
PSA:
182.79
HBD:
3.0
HBA:
#RotB:
13.0
Source:
XL-999
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Multiple Myeloma; Ovarian Neoplasms
Fibroblast growth factor receptor inhibitor
XL-999
×
Maximum Phase:
2
First Approval:
None
UNII:
6I7PLF6N8L
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ATICAPRANT
2
Small molecule
Investigational
Unknown
Unknown
Anxiety; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Tobacco Use Disorder
Kappa opioid receptor antagonist
ATICAPRANT
×
Maximum Phase:
2
First Approval:
None
UNII:
DE4G8X55F5
Molecule Type:
Small molecule
Molecular Formula:
C26H27FN2O2
Molecular Weight:
418.51
AlogP:
5.67
PSA:
55.56
HBD:
1.0
HBA:
#RotB:
6.0
Source:
VACTOSERTIB
2
Small molecule
Investigational
Unknown
Unknown
Fibromatosis, Aggressive; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms; Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung; Myeloproliferative Disorders; Stomach Neoplasms; Urinary Bladder Neoplasms
TGF-beta receptor type I inhibitor
VACTOSERTIB
×
Maximum Phase:
2
First Approval:
None
UNII:
6T4O391P5Y
Molecule Type:
Small molecule
Molecular Formula:
C22H18FN7
Molecular Weight:
399.43
AlogP:
4.24
PSA:
83.79
HBD:
2.0
HBA:
#RotB:
5.0
Source:
NCX-4016
2
Small molecule
Investigational
Unknown
Unknown
Intermittent Claudication
Unknown
NCX-4016
×
Maximum Phase:
2
First Approval:
None
UNII:
EH04H13L6B
Molecule Type:
Small molecule
Molecular Formula:
C16H13NO7
Molecular Weight:
331.28
AlogP:
2.54
PSA:
104.97
HBD:
0.0
HBA:
#RotB:
6.0
Source:
POVIDONE
2
Small molecule
Investigational
Unknown
Unknown
Thymoma; Blepharitis
Unknown
POVIDONE
×
Maximum Phase:
2
First Approval:
None
UNII:
FZ989GH94E
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CORT118335
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
CORT118335
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PRESATOVIR
2
Small molecule
Investigational
Unknown
Unknown
Respiratory Syncytial Virus Infections
Fusion glycoprotein F0 inhibitor
PRESATOVIR
×
Maximum Phase:
2
First Approval:
None
UNII:
9628AJ27JA
Molecule Type:
Small molecule
Molecular Formula:
C24H30ClN7O3S
Molecular Weight:
532.07
AlogP:
2.97
PSA:
125.93
HBD:
2.0
HBA:
#RotB:
5.0
Source:
GLPG0634
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
GLPG0634
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
OXFENDAZOLE
2
Small molecule
Investigational
Unknown
Unknown
Cysticercosis; Filariasis; Taeniasis; Helminthiasis; Infections; Trichuriasis
Unknown
OXFENDAZOLE
×
Maximum Phase:
2
First Approval:
None
UNII:
OMP2H17F9E
Molecule Type:
Small molecule
Molecular Formula:
C15H13N3O3S
Molecular Weight:
315.35
AlogP:
2.91
PSA:
84.08
HBD:
2.0
HBA:
#RotB:
3.0
Source:
HEMOGLOBIN RAFFIMER
2
Small molecule
Investigational
Unknown
Unknown
Cardiovascular Diseases
Unknown
HEMOGLOBIN RAFFIMER
×
Maximum Phase:
2
First Approval:
None
UNII:
69HRT16MGP
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
OT-551
2
Small molecule
Investigational
Unknown
Unknown
Macular Degeneration
Unknown
OT-551
×
Maximum Phase:
2
First Approval:
None
UNII:
DZ02S3A31N
Molecule Type:
Small molecule
Molecular Formula:
C13H23NO3
Molecular Weight:
241.33
AlogP:
2.35
PSA:
49.77
HBD:
1.0
HBA:
#RotB:
2.0
Source:
SAPITINIB
2
Small molecule
Investigational
Unknown
Unknown
Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Neoplasms
Epidermal growth factor receptor erbB1 inhibitor
SAPITINIB
×
Maximum Phase:
2
First Approval:
None
UNII:
3499328002
Molecule Type:
Small molecule
Molecular Formula:
C23H25ClFN5O3
Molecular Weight:
473.94
AlogP:
3.76
PSA:
88.61
HBD:
2.0
HBA:
#RotB:
7.0
Source:
KETOPROFEN SODIUM
2
Small molecule
Investigational
Unknown
Unknown
Muscular Diseases
Unknown
KETOPROFEN SODIUM
×
Maximum Phase:
2
First Approval:
None
UNII:
5R10M39KS7
Molecule Type:
Small molecule
Molecular Formula:
C16H13NaO3
Molecular Weight:
276.27
AlogP:
3.11
PSA:
54.37
HBD:
1.0
HBA:
#RotB:
4.0
Source:
(+)-SECOISOLARICIRESINOL
2
Small molecule
Investigational
Unknown
Unknown
Breast Neoplasms
Unknown
(+)-SECOISOLARICIRESINOL
×
Maximum Phase:
2
First Approval:
None
UNII:
M8QRJ7JEJH
Molecule Type:
Small molecule
Molecular Formula:
C20H26O6
Molecular Weight:
362.42
AlogP:
2.12
PSA:
99.38
HBD:
4.0
HBA:
#RotB:
9.0
Source:
RITANSERIN
2
Small molecule
Investigational
Unknown
Unknown
Cocaine-Related Disorders
Unknown
RITANSERIN
×
Maximum Phase:
2
First Approval:
None
UNII:
145TFV465S
Molecule Type:
Small molecule
Molecular Formula:
C27H25F2N3OS
Molecular Weight:
477.58
AlogP:
5.48
PSA:
37.61
HBD:
0.0
HBA:
#RotB:
5.0
Source:
PH-797804
2
Small molecule
Investigational
Unknown
Unknown
Pain; Arthritis, Rheumatoid; Neuralgia, Postherpetic; Osteoarthritis; Pulmonary Disease, Chronic Obstructive
MAP kinase p38 alpha inhibitor
PH-797804
×
Maximum Phase:
2
First Approval:
None
UNII:
GEL7GRJ3R6
Molecule Type:
Small molecule
Molecular Formula:
C22H19BrF2N2O3
Molecular Weight:
477.31
AlogP:
4.43
PSA:
60.33
HBD:
1.0
HBA:
#RotB:
5.0
Source:
NMDA
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
NMDA
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
INCB-047986
2
Small molecule
Investigational
Unknown
Unknown
Breast Neoplasms; Hodgkin Disease; Myelodysplastic Syndromes; Arthritis, Rheumatoid
Tyrosine-protein kinase JAK1 inhibitor
INCB-047986
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TEMOPORFIN
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma; Carcinoma, Non-Small-Cell Lung; Bile Duct Neoplasms; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Klatskin Tumor; Nasopharyngeal Neoplasms; Neoplasms
Photosensitizer
TEMOPORFIN
×
Maximum Phase:
2
First Approval:
None
UNII:
FU21S769PF
Molecule Type:
Small molecule
Molecular Formula:
C44H32N4O4
Molecular Weight:
680.76
AlogP:
9.76
PSA:
138.28
HBD:
6.0
HBA:
#RotB:
4.0
Source:
TETRAHYDROPALMATINE
2
Small molecule
Investigational
Unknown
Unknown
Cocaine-Related Disorders
Unknown
TETRAHYDROPALMATINE
×
Maximum Phase:
2
First Approval:
None
UNII:
3X69CO5I79
Molecule Type:
Small molecule
Molecular Formula:
C21H25NO4
Molecular Weight:
355.43
AlogP:
3.38
PSA:
40.16
HBD:
0.0
HBA:
#RotB:
4.0
Source:
FIALURIDINE
2
Small molecule
Investigational
Unknown
Unknown
Hepatitis B, Chronic; Herpes Simplex
Unknown
FIALURIDINE
×
Maximum Phase:
2
First Approval:
None
UNII:
53T7IN77LC
Molecule Type:
Small molecule
Molecular Formula:
C9H10FIN2O5
Molecular Weight:
372.09
AlogP:
-1.27
PSA:
104.55
HBD:
3.0
HBA:
#RotB:
2.0
Source:
TIDEGLUSIB
2
Small molecule
Investigational
Unknown
Unknown
Alzheimer Disease; Child Development Disorders, Pervasive; Myotonic Dystrophy
Glycogen synthase kinase-3 beta inhibitor
TIDEGLUSIB
×
Maximum Phase:
2
First Approval:
None
UNII:
Q747Y6TT42
Molecule Type:
Small molecule
Molecular Formula:
C19H14N2O2S
Molecular Weight:
334.4
AlogP:
3.26
PSA:
44.0
HBD:
0.0
HBA:
#RotB:
3.0
Source:
LAPACHONE
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma; Neoplasms
Unknown
LAPACHONE
×
Maximum Phase:
2
First Approval:
None
UNII:
6N4FA2QQ6A
Molecule Type:
Small molecule
Molecular Formula:
C15H14O3
Molecular Weight:
242.27
AlogP:
2.75
PSA:
43.37
HBD:
0.0
HBA:
#RotB:
0.0
Source:
MIVAVOTINIB CITRATE
2
Small molecule
Investigational
Unknown
Unknown
Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Ovarian Neoplasms; Lymphoma, Large B-Cell, Diffuse
Tyrosine-protein kinase SYK inhibitor
MIVAVOTINIB CITRATE
×
Maximum Phase:
2
First Approval:
None
UNII:
6ZJ8V3Q0H1
Molecule Type:
Small molecule
Molecular Formula:
C23H29FN6O8
Molecular Weight:
536.52
AlogP:
1.55
PSA:
97.86
HBD:
3.0
HBA:
#RotB:
3.0
Source:
ACETIC ACID C-11
2
Small molecule
Investigational
Unknown
Unknown
Prostatic Neoplasms, Castration-Resistant; Carcinoma, Hepatocellular
Unknown
ACETIC ACID C-11
×
Maximum Phase:
2
First Approval:
None
UNII:
2A9OM7IPNW
Molecule Type:
Small molecule
Molecular Formula:
C2H4O2
Molecular Weight:
59.05
AlogP:
0.09
PSA:
37.3
HBD:
1.0
HBA:
#RotB:
0.0
Source:
F901318
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
F901318
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SUVN-G3031
2
Small molecule
Investigational
Unknown
Unknown
Cognitive Dysfunction; Narcolepsy
Histamine H3 receptor inverse agonist
SUVN-G3031
×
Maximum Phase:
2
First Approval:
None
UNII:
65V47O9NOP
Molecule Type:
Small molecule
Molecular Formula:
C21H31N3O3
Molecular Weight:
373.5
AlogP:
2.35
PSA:
54.04
HBD:
1.0
HBA:
#RotB:
6.0
Source:
VIPIVOTIDE TETRAXETAN GALLIUM
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
VIPIVOTIDE TETRAXETAN GALLIUM
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C49H68GaN9O16
Molecular Weight:
1108.85
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
SOBLIDOTIN
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Lung Neoplasms; Sarcoma
Unknown
SOBLIDOTIN
×
Maximum Phase:
2
First Approval:
None
UNII:
DQC51A0WQH
Molecule Type:
Small molecule
Molecular Formula:
C39H67N5O6
Molecular Weight:
701.99
AlogP:
3.99
PSA:
120.52
HBD:
2.0
HBA:
#RotB:
20.0
Source:
EVODENOSON
2
Small molecule
Investigational
Unknown
Unknown
Glaucoma, Open-Angle; Ocular Hypertension
Adenosine A2a receptor agonist
EVODENOSON
×
Maximum Phase:
2
First Approval:
None
UNII:
HZ03U10J2Z
Molecule Type:
Small molecule
Molecular Formula:
C23H29N7O6
Molecular Weight:
499.53
AlogP:
-0.47
PSA:
177.95
HBD:
4.0
HBA:
#RotB:
4.0
Source:
SAF312
2
Small molecule
Investigational
Unknown
Unknown
Eye Pain; Pain; Urinary Bladder, Neurogenic
Vanilloid receptor inhibitor
SAF312
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
QUINACRINE
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Carcinoma, Renal Cell; Creutzfeldt-Jakob Syndrome; Prostatic Neoplasms, Castration-Resistant
Unknown
QUINACRINE
×
Maximum Phase:
2
First Approval:
None
UNII:
H0C805XYDE
Molecule Type:
Small molecule
Molecular Formula:
C23H30ClN3O
Molecular Weight:
399.97
AlogP:
5.97
PSA:
37.39
HBD:
1.0
HBA:
#RotB:
9.0
Source:
DEFACTINIB
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Mesothelioma; Ovarian Neoplasms
Focal adhesion kinase 1 inhibitor
DEFACTINIB
×
Maximum Phase:
2
First Approval:
None
UNII:
53O87HA2QU
Molecule Type:
Small molecule
Molecular Formula:
C20H21F3N8O3S
Molecular Weight:
510.5
AlogP:
2.4
PSA:
142.1
HBD:
3.0
HBA:
#RotB:
8.0
Source:
1
2
…
105
106
107
108
109
110
111
…
186
187
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA